Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIR-T CD19xCD20xCD22
- Development stage
- Preclinical
- Lead developer
- Angeles Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
SIR-T CD19xCD20xCD22 is a preclinical-stage trispecific cell therapy developed by Angeles Therapeutics. It utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which is designed to provide more physiological T-cell activation compared to traditional CAR-T constructs by mimicking natural T-cell signaling. This specific candidate is engineered to simultaneously recognize and target three distinct B-cell antigens: CD19, CD20, and CD22. This multi-antigen targeting approach is intended to enhance therapeutic efficacy and prevent tumor relapse caused by antigen escape, a frequent challenge in the treatment of B-cell lymphomas and leukemias.
- Other names
- SIR-T CD19xCD20xCD22
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on SIR-T CD19xCD20xCD22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIR-T CD19xCD20xCD22.